Overview
Hyponatremia, a condition characterized by significantly low levels of sodium in the blood, is a known indicator of poorer health outcomes in non-small cell lung cancer. Emerging biological research suggests that blood sodium levels may influence how well the immune system fights tumors, but large-scale evidence examining its impact on patients receiving modern immunotherapy has been lacking.
Researchers analyzed real-world data from the Flatiron Health Research Database, examining patients with metastatic non-small cell lung cancer across the United States, United Kingdom, and Germany who received first-line immunotherapy. Low serum sodium was detected in 18% to 23% of patients at the start of treatment. After adjusting for clinical factors, low sodium levels were significantly associated with shorter overall survival among U.S. patients, with consistent trends observed in the European cohorts.
Why this matters
This study suggests that serum sodium can serve as a valuable prognostic marker for patients starting immunotherapy for advanced non-small cell lung cancer. Recognizing low sodium as a risk factor allows clinicians to better identify vulnerable patients early, tailor supportive care, and refine treatment monitoring to improve patient management.